BIO-GENE TECHNOLOGY LIMITED (ASX : BGT)

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

May 2022

CORPORATE PRESENTATION

PRESENTED BY

Richard Jagger

Chief Executive Officer &
Managing Director

DISCLAIMER

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitution a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. no representation, warranty or guarantee, express or implied, is given that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

ADDRESSING SIGNIFICANT GLOBAL CHALLENGES

The effectiveness of current insecticides is diminishing due to resistance & concerns relating to safety profiles

Food Security & Public Health

Growing Population	Current global population is 7.7 billion, growing at 70 million p.a. It is anticipated that global population will reach nearly 10 billion by 2050[1].
Challenges Of Climate Change	Climbing average temperatures and other weather events impact food production per hectare, increase the habitable environment for mosquitoes

Financial Impact

Production	Currently 20-40% of food produced globally is lost to pests, valued at around US$2000 billion p.a.[2,3] .
Cost/Benefit	Direct costs due to Malaria infections valued at US$12 billion p.a., with economic impact many times that [4]

Social Impact

Vector Borne Disease	More than half the world is at risk[5;] account for 25% of infectious diseases and exacerbate poverty & economic hardship. Potential to grow beyond 50% under climate change scenarios[6]
Less Arable Land	Increased population puts pressure on available land and resources to produce food for today and tomorrow

1. United Nations, "World Population Prospects 2019"
2. Oerke EC, Crop Losses to pest J. Agri Sci 144: 31-43 (2005)
3. Pimentel D Pesticides and Pest controls. In: Peshin R, Dhawan AK. (eds). Integrated pest management: innovation-development process, 1:83-87. Springer Science (2009)
4. CDC: Malaria's impact worldwide
5. WHO report, 2015
6. 6. IPCC6th assessment report: Climate Change 2022: Impacts, Adaptation and Vulnerability, February 2022

OUR TECHNOLOGY PLATFORM

We are developing two products that allow entry into five key market segments



Qcide™

Natural Compound

An extract of a specific cultivar of eucalypt, the Gypmie Messmate

Trees are farmed in concentration by sub-contractors in QLD

The leaves contain oil expressing high levels of Tasmanone, a natural compound that has shown evidence of insecticide efficacy

Flavocide™

Nature Identical Compound

BGT has developed a proprietary chemical process with CSIRO to to deliver another Beta-Triketone; a nature identical compound that is able to be produced at commercial scale

Both of our products have potential application in all five of our target market segments

OUR PROPRIETARY CHEMISTRY REPRESENTS A STEP-CHANGE FOR RESISTANT PEST CONTROL

Naturally Derived Chemistry

Qcide is a natural compound and Flavocide is a 'nature identical mimic' of a natural compound that can be mass produced

Safe Chemistry

Excellent safety profile based on data generated to date. Low toxicity to bees & beneficial insects (5000 times less toxic to bees than neonicotinoids)

Efficacy

Testing to date confirms potential for controlling resistant pests across multiple markets

Novel Mode of Action

Operates via a novel Mode of Action, potentially addressing resistance to other classes of chemistry

Last new Mode of Action was 2008, now selling US$2.3 b annually

Multiple Global markets

Bio-Gene's insecticide platform has applications across large, global market segments valued at over US$31.1 billion p.a.

Current & future partnerships

We currently have agreements with a number of large companies covering the testing our technology; collaborative development programs and options on future commercial rights

OUR TECHNOLOGY ADDRESSES THESE CHALLENGES AND TARGETS GROWING GLOBAL MARKETS



Bio-Gene's insecticide platform has potential application in large, global market segments estimated to represent a total addressable market valued at over US$31.1 billion

US EPA 2017, WHO 2017, Zoetis & Provue Market Research, Markets & Markets

OUR STRATEGIC OBJECTIVE

Generate multiple revenue streams from technology licensing fees, milestone payments and royalties by

Securing & owning active ingredient product registrations

Working with strong commercial partners on product development; marketing and distribution

Developing proprietary manufacturing and production know-how

Potential partnership agreements across multiple geographies and different end-use markets, with collaboration programs now underway in two of our target segments

SIGNIFICANT POSITIVE PROGRESS ACROSS MULTIPLE FRONTS

BGT continues to execute on a strategy to secure commercial partnerships that help validate our technology and establish meaningful future value streams

Australian technology with the potential to make a global difference

New, natural and novel chemistry has the opportunity to address resistance issues impacting food security and public health

New agreements with commercial partners

Development agreements	BGT has executed a commercial development agreements with Evergreen Garden Care and Clarke Mosquito Control
Additional MTAs	BGT has entered into new Material Transfer Agreements (MTAs) with large international companies focused across the various market segments where our technology has potential application

Funding

Capital raise of $3.2 million late 2021 & $1.5 million strategic placement in March 2022. R&D tax incentive rebate of $514,000 in March 2022

Building our efficacy data

Recent results	Positive results from the Phase 2 studies undertaken with Clarke on mosquito control. Stored grain pest control via QDAF 9 month study results released
Regulatory support	Completion of independent review by CRO to determine optimal pathway for US and European active ingredient registration. Appointment of Bio-Gene Head of Global Regulatory Affairs

Strengthening our IP

New patents	US Patent Office grants patent relating to management of pesticide resistant insects using Bio-Gene molecules. Allowances in Australia, submissions in other geographies
Additional IP	Programs underway to strengthen IP relating to manufacturing and extraction processes

CONSUMER PRODUCTS: EVERGREEN COMMERCIAL DEVELOPMENT AGREEMENT

Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand

Initial Field of Use

Fly & mosquito electric evaporator

Ant bait gel and ant spray

ROFR to negotiate additional applications within consumer market

Initial Territory

E.U., U.K., A/NZ

ROFR to negotiate additional territories within consumer market

Revenue Model

Up-front licence fee

Milestone payments prior to registration

On-going royalties on end-use product sales

Development costs borne by Evergreen

Market Opportunity

Initial Field of Use: US$600m[1]

Total European consumer insecticide market: US$2b[1]

EVERGREEN Garden Care

1. Research and Markets report, December 2019: *Europe Household Insecticides Market to 2027 - Regional Analysis and Forecasts By Insect Type; Composition; Packaging; Distribution Channel*.

PUBLIC HEALTH: NEW COMMERCIAL AGREEMENT SIGNED ON CLARKE MOSQUITO PROJECT

Clarke is the largest vertically integrated company in public health mosquito control

Results of Phase 2 Testing

Very positive results indicate the suitability of Bio-Gene products as mosquito control technology

Target formulations identified for progression to Phase 3 field trials

Confidence for both companies has allowed for completion of commercial agreement

New Commercial Agreement Signed

Allows Clarke to begin Phase 3 field testing

Agreement is for the U.S. and Cayman Islands market

Cost of studies borne by Clarke, with shared report of results

Licence fee payments from Clarke to Bio-Gene over the next 3 years

On-going royalties on end-use-product sales by Clarke

Next Steps

Combined Clarke / Bio-Gene team to focus on registration process of Active Ingredient and development and registration of end use products

Field studies designed to confirm suitability of laboratory developed formulations for field use & EPA registration

Market Opportunity

Initial Field of Use: US$100m[1]

Global market $650m[1]

[1] *Global Mosquito Control Market, Research Report 2020, Forecast to 2026*

CROP PROTECTION: UPDATE ON STORED GRAIN PROJECT

Grains research and Development Corporation (GRDC)
Department of Agriculture and Fisheries - Queensland (DAF)

Results of Phase 3 testing

Data show the ability for Flavocide, when used in combination (at low rates) to control the full range of stored grain pests over 9 months for susceptible strains and 3-9 months for resistant strains (commercially acceptable time frame).

Further Discussions

Bio-Gene is discussion next steps with potential commercial partners to progress the commercial development of Flavocide as a stored grain protectant

Next we will discuss support from the GRDC

GRDC
GRAINS RESEARCH & DEVELOPMENT CORPORATION

QUEENSLAND GOVERNMENT
Department of Agriculture and Fisheries

Field testing completed Nov/Dec 2021

Final reporting on these results reported in March 2022

Positive outcome allows us to move forward

Market opportunity in Australia is relatively small, but there is significant global potential (A$1b)[1]

1 Market and markets report – grain protectants global market forecast to 2023

IMPORTANT PROGRESS ACROSS OTHER KEY AREAS

I.P. Developments

- Additional research underway has the potential to identify new I.P. for the company
- I.P. can be in the form of patents, technical knowhow, trade secrets

Review Of Reg Requirements

- Completed a regulatory review analysis with global consultants to look at the specific data requirements for USA, European Union, Australia across our different market segments
- Clear understanding developed relating to read-across potential for different applications and regulatory jurisdictions.

Additional MTAs

- Bio-Gene has signed 4 new MTAs in the past year with international companies focused across all areas of insecticide use
- Studies performed by these companies ultimately give Bio-Gene additional options for going to market

Manufacturing

- Flavocide manufacturing validation – scale-up process has confirmed ability to produce larger quantities
- Qcide: Last harvest confirmed production improvements based on modified temperature and pressure

Efficacy testing

- Additional studies underway for specific company evaluation of technology
  - Animal Health
  - Consumer
  - Crop Protection
  - Public Health
- Extension work to identify additional key targets and applications to support our commercial discussions and further develop our I.P. portfolio

Patent Allowances

- 2 granted in Australia
- 1 recently granted in United States
- Under review in other key markets

On-going research is focused on developing data to support key commercial discussions as well as enhancing our I.P. portfolio

Bio-Gene continues to expand its market network and identify new data that further differentiates our I.P. position

POSITIVE NEWS FLOW AS WE CONTINUE TO EXECUTE ON THE STRATEGY

2021& 2022 Announcements have included

Mode of Action	✓ Positive results to confirm novel Mode of Action
Efficacy	✓ Positive efficacy data in the 9 month stored grain pest control study
Intellectual Property	✓ Several new patent allowances and grants that strengthen our IP
Commercial	✓ Commercial agreement executed with Evergreen Garden Care ✓ Commercial agreement executed with Clarke Mosquito Control
Resourcing	✓ Appointment of Head of Global Regulatory affairs ✓ Cap raise of $3.2 million & $1.5 m strategic placement, and R&D tax incentive - $514,000

Upcoming News Flow

Efficacy	❑ Results of ongoing research work at Purdue University and University of Florida
Commercial	❑ Next steps in collaboration with BASF on stored grain pest opportunity ❑ Updates on new MTA evaluations and next steps
Intellectual Property	❑ Feedback on additional patent allowances in various world regions
Manufacturing	❑ Developments relating to manufacturing process improvements for Flavocide and Qcide

A CLEAR ROAD MAP FOR GENERATING VALUE – MEDIUM TERM

2018-2020

- Proof of principle efficacy testing
- Preliminary safety data
- Product formulation concepts
- Testing with 3rd parties

2020-2021

- Efficacy data in multiple settings
- Advancing safety and tox testing
- Confirming novel Mode of Action claims
- Development agreements and additional MTAs

2021-2022

- Manufacturing scale-up
- Building regulatory data package
- Securing initial agreements with commercial partners
- Converting additional MTAs into collaborative development agreements

2022-2024

- Additional application testing - internal and with partners
- Applying for formal recognition of novel Mode of Action
- Completing data package for final submission

2024-2026

- First regulatory approval and commercial sales
- Additional registration submissions
- Potential new product development program

Incremental Value

POTENTIAL UPFRONT AND MILESTONE PAYMENTS, LICENSING FEES → AND ROYALTIES

FUNDING POSITION

Shares on issue

179,056,519

Market capitalisation

$51 million[1]

As at March 31, 2022,
Cash on hand

A$7.2 million

Provides working capital needs on budgeted activities well beyond

12 months

1. @28.5 cents per share

Sources of future funding:

- Development and commercial partnerships
- Government grants
- Philanthropic organisations focused on public health solutions
- Industry organisations
- Capital markets

BOARD MEMBERS & MANAGEMENT

Robert Klupacs

Chairman

- 30+ years corporate experience in international tech development
- Previously MD & CEO of ASX-listed Circadian Technologies Ltd and MD & CEO of ES Cell International Pte Ltd
- Registered Australian patent attorney

Richard Jagger

CEO & Managing Director

- 25+ years working in agriculture globally
- Most recently employed as Managing Director of Sinochem Australia
- Previously spent 15+ years at Monsanto in various management roles
- Director, Agriculture Victoria Services

Peter Beetham

Non-Executive Director

- 30+ years experience in bio-agriculture community
- CEO of Cibus Global
- Previously Scientific Officer at Plant Research Institute, Victorian Dept Ag

Andrew Guthrie

Non-Executive Director

- 32 years experience in agriculture globally
- Management roles in multiple geographies
- Was part of Syngenta's leadership team responsible for business strategy that leveraged R&D capability to invent, gain regulatory approval and launch new products.

Peter May

Executive Director, R & D

- 20+ years experience in crop protection market with companies Orica & Crop Care Australasia (now Nufarm)
- Founded Xavca, consulted to companies such as Syngenta & Sorex (BASF)
- Former CEO & Chairman of BioProspect (now Medibio, ASX:MEB)

James Joughin

Non-Executive Director

- Highly experienced ASX listed and private company Director.
- Currently the Non-Exec Chair at Spirit Technology Solutions Ltd (ASX:ST1) and a NED at Mydeal.com.au Ltd (ASX:MYD)
- Former partner in Big 4 firm with expertise in capital markets etc.

Roger McPherson

CFO & Co. Sec.

- 15+ years experience as CFO & Company Secretary across both listed & unlisted companies
- Experience in the pharma manufacturing, biotech & biopharma industries
- Previously CFO & Co-Sec of TPI Enterprises (ASX:TPE)

James Wade

Program Manager

- PhD with 10+ years experience in research in a broad range of agricultural verticals
- Previously Science and Technology Program Manger for Avigen Ltd

Sarah Driessens

Head of Regulatory

- Master with 10+ years of Regulatory experience at Monsanto (and subsequently Bayer after the Monsanto acquisition)
- Company representative at different industry associations (Phytofar, Nefyto, European Crop protection association,..)

BIO-GENE TECHNOLOGY LIMITED

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

CONTACT

RICHARD JAGGER
CHIEF EXECUTIVE OFFICER

richardj@bio-gene.com.au